Evidence map›Paper›PMID 35466408›Full record

ArticleJournal of veterinary pharmacology and therapeutics2022

Pharmacokinetics of single and repeated oral doses of pregabalin oral solution formulation in cats.

Terttu Lamminen, Anne Doedée, Minja Hyttilä-Hopponen, Janne Kaskinoro

Open access · hybridAbstract read
In one paragraph

Article in Journal of veterinary pharmacology and therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Terttu LamminenR&D, Orion Corporation Orion Pharma, Espoo, Finland.ORCID https://orcid.org/0000-0003-2156-7965
Anne DoedéeCharles River Laboratories Den Bosch B.V., 's-Hertogenbosch, The Netherlands.
Minja Hyttilä-HopponenR&D, Orion Corporation Orion Pharma, Espoo, Finland.
Janne KaskinoroR&D, Orion Corporation Orion Pharma, Espoo, Finland.
Orion Corporation (Finland) · FICharles River Laboratories (Netherlands) · NL

Funding

Orion Corporation Orion Pharma
6 · The paper itself

Abstract

The study was designed to determine the pharmacokinetic profile and bioavailability of a novel pregabalin 50 mg/ml oral solution formulation (Bonqat

Indexed as

PregabalinAdministration, IntravenousAdministration, OralAnimalsArea Under CurveBiological AvailabilityCatsHalf-LifePregabalincatpharmacokineticspregabalinrepeated oral dosesingle oral dose

Identifiers

PMID35466408
PMCPMC9545034
OpenAlexW4224308721

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.